Stroke and Hemorrhage Risks of NOACs in Younger NVAF Patients

Overview

This cohort study evaluated the comparative safety and effectiveness of standard-dose non-vitamin K oral anticoagulants (NOACs) in patients aged 21 to 64 years with nonvalvular atrial fibrillation (NVAF). Using FDA Sentinel System data, the study assessed risks of major extracranial bleeding, intracranial hemorrhage, gastrointestinal bleeding, and thromboembolic stroke among users of dabigatran, rivaroxaban, and apixaban.

Background

NOACs are widely used for stroke prevention in NVAF and have demonstrated reduced intracranial bleeding compared to warfarin in randomized trials. However, direct comparisons of NOACs regarding bleeding risk and stroke prevention, especially in patients younger than 65 years, remain limited. Observational studies have been constrained by small sample sizes, confounding, and design limitations. The FDA Sentinel System provides a large, real-world data source to evaluate NOAC safety and effectiveness in this younger population.

Data Highlights

The study included standard-dose NOAC initiators aged 21 to 64 years from October 2010 to February 2022 across five data partners. Outcomes assessed were major extracranial bleeding (including gastrointestinal bleeding), intracranial hemorrhage, and thromboembolic stroke, identified using validated algorithms with high positive predictive values. Follow-up continued until outcome occurrence, anticoagulant switching, disenrollment, death, or end of data availability. Three pairwise comparisons were conducted: rivaroxaban vs dabigatran, rivaroxaban vs apixaban, and dabigatran vs apixaban.

Key Findings

• Rivaroxaban was associated with a less favorable benefit-harm profile compared to other NOACs in patients aged 65 years or older; this study extends evaluation to younger patients aged 21-64 years.
• Major extracranial bleeding, intracranial hemorrhage, and thromboembolic stroke were reliably identified using validated ICD-9-CM and ICD-10-CM coding algorithms.
• Patients with prior anticoagulant use, dialysis, alternative anticoagulation indications, or institutional stays were excluded to focus on new NOAC users with NVAF.
• Standard dosing definitions were dabigatran 150 mg twice daily, rivaroxaban 20 mg once daily, and apixaban 5 mg twice daily; edoxaban was excluded due to low usage.
• Follow-up accounted for continuous exposure with a 3-day gap allowance based on NOAC half-lives to accurately capture treatment episodes.

Clinical Implications

Clinicians should consider the comparative safety profiles of NOACs when prescribing for younger NVAF patients, as bleeding and stroke risks may differ among agents. The FDA Sentinel System data support informed decision-making by providing real-world evidence beyond older populations. Careful patient selection and monitoring remain essential to optimize anticoagulation benefits while minimizing harms.

Conclusion

This large cohort study leveraging FDA Sentinel System data provides important comparative safety and effectiveness insights for NOAC use in younger patients with NVAF. These findings help fill knowledge gaps and guide anticoagulant selection in this demographic.

References

1. FDA Sentinel System -- Active Surveillance for FDA-Regulated Products
2. Cunningham et al. 2011 -- Validation of Bleeding Algorithms
3. STROBE Statement -- Reporting Observational Studies